LeonaBio, Inc.

EFFECT effective

LeonaBio, Inc. has received effectiveness for its S-1 registration statement, converting a prior S-3 filing into an S-1. The prospectus outlines the potential offering of 58,464,567 shares of common stock by selling stockholders, including proceeds from warrant exercises. The company, a clinical-stage biopharmaceutical firm, focuses on developing therapies for treatment-resistant metastatic breast cancer and ALS, with lead candidates lasofoxifene and ATH-1105. The filing emphasizes risks associated with its early-stage development and regulatory uncertainties.

EFFECT effective

LeonaBio, Inc. filed an S-1 registration statement with the SEC, which became effective on April 1, 2026. The filing confirms the company's eligibility to offer securities to the public, with the same effectiveness date as the previous submission. The current filing includes the same basic details as the prior version, including the company's CIK and SEC file number.

S-1/A amended

LeonaBio, Inc. filed a pre-effective amendment (S-1/A) to convert its prior S-3 registration statement into an S-1 form, reflecting its transition from a smaller reporting company to a public offering. The filing relates to the resale of 5,502,402 shares of common stock issuable upon exercise of a pre-funded warrant, with no proceeds going to the company from the selling stockholder's sales. The company, formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical firm focused on developing therapies for treatment-resistant metastatic breast cancer and ALS.

S-1/A amended

LeonaBio, Inc. filed a Pre-Effective Amendment No. 1 to convert its S-3 registration statement into an S-1, reflecting a shift in its IPO strategy. The current filing details the offering of 58,464,567 common shares, including shares from pre-funded warrants and warrants, following a December 2025 private placement (PIPE) involving $90 million in proceeds. The company highlights its clinical-stage biopharmaceutical focus on treatments for metastatic breast cancer and ALS, with key drug candidates lasofoxifene and ATH-1105. The filing also outlines terms for warrant exercises tied to clinical trial milestones and regulatory approvals.

EFFECT effective

The current filing is a Notice of Effectiveness for Athira Pharma, Inc. (CIK: 0001620463) for a Form S-3 registration, effective October 28, 2024. This follows a prior effectiveness notice dated November 24, 2021, for the same company and form, indicating ongoing regulatory compliance for securities offerings.

EFFECT effective

The current filing is a Notice of Effectiveness for Athira Pharma, Inc.'s Form S-3 registration statement, effective November 24, 2021. This follows a previous 424B4 filing from January 2021, which detailed an offering of 4 million shares of common stock at $22.50 per share, with underwriting discounts and proceeds to the company. The current filing primarily confirms regulatory effectiveness without additional operational or financial details.

424B4 priced

LeonaBio, Inc. is offering 4,000,000 shares of common stock at $22.50 per share, with underwriters having an option to purchase an additional 600,000 shares. The company, an emerging growth company, is focused on developing small molecules targeting neurodegenerative diseases via HGF/MET signaling. The filing highlights ongoing Phase 2/3 trials for ATH-1017 in Alzheimer’s disease, with potential pivotal data expected by 2022. Proceeds will fund clinical trials, research, and operations.

EFFECT effective

Athira Pharma, Inc. filed an S-1 registration statement for its IPO, disclosing an offering of 4,000,000 shares of common stock at an estimated price of $26.01 per share, with a maximum aggregate offering price of $119,646,000. The company, a late clinical-stage biopharmaceutical firm focused on neurodegenerative diseases, aims to restore neuronal health via HGF/MET signaling. The filing includes a prospectus summary, risk factors, and details about its lead candidate, ATH-1017, which showed tolerability in Phase 1 trials for Alzheimer’s disease.

S-1 filed

Athira Pharma, Inc. is a biopharmaceutical company developing small molecules to restore neuronal health and combat neurodegeneration via HGF/MET signaling. Its lead candidate, ATH-1017, is in Phase 2/3 trials for Alzheimer’s disease (AD) and has shown improved brain function metrics. The company is offering 4.6 million shares (including 600,000 underwriter options) with a proposed max offering price of $26.01. It is an emerging growth company with a focus on CNS and peripheral nervous system disorders, including Parkinson’s disease dementia and neuropathy.

DRS filed

The current filing is a Form S-1 registration statement for Athira Pharma, Inc., disclosing an offering of common stock. The company is a biopharmaceutical firm focused on developing small molecules to restore neuronal health via HGF/MET signaling, with lead candidate ATH-1017 in Phase 2/3 trials for Alzheimer's disease. The filing emphasizes ongoing clinical trials, including LIFT-AD (Phase 2/3) and ACT-AD (Phase 2), and highlights preliminary positive results in P300 latency and gamma power improvements. The company remains an emerging growth company with reduced reporting requirements.

424B4 priced

Athira Pharma, Inc. is conducting an initial public offering (IPO) of 12,000,000 shares of common stock at $17.00 per share, with proceeds totaling $189.7 million after underwriting discounts. The company, a biopharmaceutical firm focused on neurodegenerative diseases, is listing on the Nasdaq Global Select Market under the ticker 'ATHA.' Its lead candidate, ATH-1017, is in Phase 2/3 trials for Alzheimer’s disease, with interim results expected by late 2022. The filing emphasizes the company’s status as an emerging growth company and highlights risks related to clinical trial outcomes, regulatory approval, and dependence on a single product candidate.

EFFECT effective

Athira Pharma, Inc. filed a Form S-1 registration statement for an initial public offering (IPO) of 10,000,000 shares of common stock, with an option for underwriters to purchase an additional 1,500,000 shares. The offering price is estimated between $15.00 and $17.00 per share, with the company aiming to list on the Nasdaq Global Market under 'ATHA.' The filing highlights the company's focus on developing small molecules targeting neurodegenerative diseases via the HGF/MET pathway, with its lead candidate ATH-1017 in clinical trials. The company is classified as an emerging growth company under SEC regulations.

S-1/A amended

Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecules to restore neuronal health and address neurodegenerative diseases via the HGF/MET pathway. The company is conducting clinical trials for ATH-1017, a candidate for Alzheimer’s disease (AD), with Phase 2/3 trials (LIFT-AD) expected to yield pivotal data by late 2022. The S-1/A filing outlines an IPO of 10 million shares at an estimated price range of $15–$17, with proceeds intended for clinical development, manufacturing, and general expenses. Athira is an emerging growth company with no revenue to date and significant risks related to clinical trial outcomes and regulatory approval.

S-1/A amended

Athira Pharma, Inc. is a biopharmaceutical company focused on developing small molecules to restore neuronal health and address neurodegenerative diseases. Its lead candidate, ATH-1017, is a BBB-penetrating HGF/MET activator in Phase 1/2 trials for Alzheimer's disease, showing improved cognitive metrics. The company is preparing for an IPO, aiming to raise $195.5 million, and plans Phase 2/3 trials for AD and other indications. It remains an emerging growth company with no revenue and significant reliance on clinical trial success.

8-A12B effective

Athira Pharma, Inc. filed an 8-A12B form to register its common stock under Section 12(b) of the Securities Exchange Act, referencing its prior S-1 registration statement. The filing incorporates by reference the capital stock description from the S-1, which detailed its biopharmaceutical pipeline targeting neurodegenerative diseases via HGF/MET signaling. No new material information is provided beyond the S-1, and no exhibits are required.

S-1/A amended

The current S-1/A filing represents an amendment to Athira Pharma, Inc.'s initial registration statement for an IPO, focusing on adding exhibits and supplementary disclosures. The previous 8-A12B filing was a simpler registration of securities under Section 12(b) of the Exchange Act. The S-1/A includes detailed information on underwriting agreements, indemnification provisions, recent unregistered securities sales, and other expenses, indicating preparation for a public offering. The company remains in a development stage with no revenue, relying on private financings and equity incentives.

S-1 filed

Athira Pharma, Inc. is a biopharmaceutical company developing small molecules to restore neuronal health and address neurodegenerative diseases. Its lead candidate, ATH-1017, is in Phase 1 trials for Alzheimer's disease (AD) and shows potential to improve brain function via HGF/MET pathway activation. The company plans to advance ATH-1017 to Phase 2/3 trials for AD and initiate Phase 2 trials for Parkinson's disease dementia (PDD) by 2021. The S-1 filing outlines an IPO for common stock, with proceeds intended for clinical development and operational expansion.

DRS filed

Athira Pharma, Inc. is preparing for its initial public offering (IPO) to raise capital for advancing its late-stage biopharmaceutical pipeline focused on neurodegenerative diseases. The company's lead candidate, ATH-1017, a small-molecule HGF/MET activator, has completed Phase 1a/1b trials for Alzheimer's disease (AD) with positive safety and preliminary efficacy signals, including improved brain activity metrics. The company plans to initiate pivotal Phase 2/3 trials for AD in 2020 and is exploring applications for Parkinson’s disease dementia (PDD) and peripheral neuropathy. Athira is an emerging growth company, leveraging its proprietary ATH platform to target neuronal health through HGF/MET signaling, with a focus on BBB-penetrating compounds.